fashion -WSS

fashion

author：fashion 2025-09-29 16:44:49 - browse：99685

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Will the IRA bring competition to the biologics market?

WSS

Poland's lawmakers approve a divisive law on Russian influence

Poland's lawmakers approve a divisive law on Russian influence

How housing is health care on Long Island

Regeneron agrees to White House price limits on anti

Regeneron agrees to White House price limits on anti

What AstraZeneca

Wikipedia

fashion

knowledge

Apple is now the first public company to be valued at $3 trillion

Food makers to regulators: Ultra

Activists slam private health insurers over coverage restrictions

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

DIEP, the 'gold standard' of breast reconstruction, is under threat

Trump team launching legal defense fund to help pay legal bills

Walensky prepares to leave CDC — and Congress — behind

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Virginia high school admissions case could be legal follow

PEPFAR is under serious threat — and so is global health

explore

Europe is fastest

New weight loss drugs vying to be the next Wegovy or Mounjaro

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

A common UTI test for kids haunts adults as a traumatic 'nightmare'

How to make the FDA’s new prescription one

How housing is health care on Long Island

focus

hotspot

leisure time

focus